GLP-1 receptor agonists and SGLT-2 inhibitors deliver benefits that matter most to patients — reduced heart and kidney disease, less depression, better quality of life, and simpler treatment regimens.
Beyond blood sugarGLP-1 drugs and SGLT-2 inhibitors reduce heart disease, kidney disease, depression, cognitive decline, and treatment complexity — outcomes patients value most
What the researchers found
SGLT-2 inhibitors and GLP-1 receptor agonists provide cardiovascular and renal protection beyond glucose lowering, reduce body weight and hypoglycemia risk, and improve diabetes-related distress, physical function, and health-related quality of life. Combined with basal insulin/GLP-1RA combinations, they enable treatment simplification from high-dose multi-injection insulin regimens. Additional benefits include reduced incidence of depression, cognitive decline, respiratory disease, gout, and arrhythmias — addressing the multimorbidity burden that complicates type 2 diabetes and degrades quality of life.
Why it matters
Diabetes management has historically focused on blood sugar numbers, but patients care more about how they feel, whether they'll have a heart attack, and how complicated their treatment is. This review makes the case for a paradigm shift — using GLP-1 drugs and SGLT-2 inhibitors earlier and more broadly because they improve the outcomes that actually matter to patients.
How the study worked
Narrative review synthesizing evidence from cardiovascular outcome trials, quality of life studies, and clinical research on the pleiotropic effects of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
What this study cannot tell us
This is a narrative review without systematic methodology. The breadth of claimed benefits — from depression to gout to cognitive decline — draws from studies of varying quality and evidence strength. Some pleiotropic benefits are based on observational data and require confirmation in dedicated clinical trials. The review does not address cost barriers or access issues that limit real-world adoption.
How to read the evidence
This is a narrative review drawing on evidence from major cardiovascular outcome trials (high quality) alongside observational studies of pleiotropic effects (moderate quality). The overall argument is well-supported for cardiovascular and renal benefits but more speculative for some other claimed benefits.
When this study was published
Published in 2024, this review reflects the current evidence-based rationale for prioritizing GLP-1 drugs and SGLT-2 inhibitors in diabetes management guidelines.
The bigger picture
This review reflects a fundamental shift in diabetes care philosophy — from glucose-centric to outcome-centric management. The recognition that GLP-1 drugs and SGLT-2 inhibitors address multimorbidity (the co-occurrence of multiple chronic conditions) positions them as foundational treatments for the complex reality of type 2 diabetes, not just add-ons for blood sugar control.
Questions still open
- Should GLP-1 drugs and SGLT-2 inhibitors be prescribed to all type 2 diabetes patients at diagnosis regardless of cardiovascular risk?
- How much of the quality of life improvement is from the drugs themselves versus from simplifying insulin regimens?
- Will next-generation multi-agonist peptides (like triple GIP/GLP-1/glucagon agonists) amplify these patient-important benefits further?
Common questions
Why should diabetes drugs be judged on more than blood sugar?
Can GLP-1 drugs replace insulin entirely?
Read the original research
Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
Diabetes & vascular disease research, 21(4), 14791641241269743
Citation
Kintzoglanakis, Kyriakos; Diamantis, Christos; Mariolis, Anargiros; Paschou, Stavroula A. (2024). Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.. Diabetes & vascular disease research, 21(4), 14791641241269743. https://doi.org/10.1177/14791641241269743